Statin Use and the Risk of Incident Diabetes Mellitus: A Review of the Literature

Canadian Journal of Cardiology

Volumn 28, Issue 5, 2012, Pages 581-589

  Colbert, Jillian D ^a   Stone, James A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATIN; TRIACYLGLYCEROL;

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR MORTALITY; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HIGH RISK POPULATION; HUMAN; HYPERTRANSAMINASEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; REVIEW; RHABDOMYOLYSIS; SECONDARY PREVENTION; SIDE EFFECT; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

DIABETES MELLITUS; DISEASE SUSCEPTIBILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK MANAGEMENT;

EID: 84866370223     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.03.021     Document Type: Review

References (52)

1. Mills E., Wu P., Chong G., et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials. Q J Med 2011, 104:109-124.
2. Ridker P.M., Danielson E., Fonseca F.A.H., et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009, 373:1175-1182.
3. Baigent C., Blackwell L., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet 2010, 376:1670-1681. Cholesterol Treatment Trialists Collaboration.
4. FDA Drug Safety Communication: Important Safety Label Changes to Cholesterol-Lowering Statin Drugs Available at, Accessed February 28, 2012. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm.
5. Coleman C., Reinhart K., Kluger K., White C.M. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2008, 24:1359-1362.
6. Preiss D., Seshasai S., Welsh P., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011, 305:2556-2564.
7. Sattar N., Preiss D., Murray H., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735-742.
8. Rajpathak S., Kumbhani D., Crandall J., et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009, 32:1924-1929.
9. Freeman D., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357-362.
10. Wong V., Stavar L., Szeto L., et al. Atorvastatin induces insulin sensitization in Zucker lean and fatty rats. Atherosclerosis 2006, 184:348-355.
11. Koh K., Quon M., Ha S., et al. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 2010, 55:1209-1216.
12. Waters D., Ho J., DeMicco M., et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011, 57:1535-1545.
13. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
14. Pedersen T.R., Faergeman O., Kastelein J.J.K., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. JAMA 2005, 294:2437-2445.
15. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006, 355:549-559. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.
16. Sever P., Dhlof B., Poulter N., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized control trial. Lancet 2003, 361:1149-1158.
17. McCarey D.W., McInnes I.B., Madhok R., et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004, 363:2015-2021.
18. Paul F., Waiczies S., Wuerfel J., et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One 2008, 3:e1928.
19. Martin S., Herder C., Schloot N., et al. Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial. PLoS One 2011, 6:e17554.
20. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357:2248-2261.
21. Keech A., Colquhoun D., Best J., et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003, 26:2713-2721.
22. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high risk individuals: a randomized placebo controlled trial. Lancet 2002, 360:7-22. Heart Protection Study Collaborative Group.
23. Armitage J., Bowman L., Wallendszus K., et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial (SEARCH). Lancet 2010, 376:1658-1669.
24. Koh K., Quon M., Han S., et al. Simvastatin improves flow mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 2008, 31:776-782.
25. Culver A., Ockene I., Balasubramanian R. Statin use and risk of diabetes mellitus in postmenopausal women in the women's health initiative. Arch Intern Med 2012, 172:144-152.
26. Mancini G.B., Schulzer M. Reporting risks and benefits of therapy by use of the concepts of unqualified success and unmitigated failure: applications to highly cited trials in cardiovascular medicine. Circulation 1999, 99:377-383.
27. Schulzer M., Mancini G.B. 'Unqualified success' and 'unmitigated failure': number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events. Int J Epidemiol 1996, 25:704-712.
28. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
29. Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2008, 32(suppl 1):S1-S201. Accessed May 2012. http://www.diabetes.ca/files/cpg2008/cpg-2008.pdf.
30. Opie L.H., Schall R. Old antihypertensives and new diabetes. J Hypertens 2004, 22:1453-1458.
31. Padwal R., Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes. Diabetes Care 2004, 27:247-255.
32. Abuissa H., Jones P.G., Marso S.P., O'Keefe J.H. Angiotensin-converting enyzme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005, 46:821-826.
33. Elliott W., Meyer P. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007, 369:201-207.
34. Bosch J., Yusuf S., et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006, 355:1551-1562. DREAM Trial Investigators.
35. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.
36. Yada T., Nakata M., Shiraishi T., et al. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol 1999, 126:1205-1213.
37. Ishikawa M., Okajima F., Inoue N., et al. Distinct effects of pravastatin, atorvas- tatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. J Atheroscler Thromb 2006, 13:329-335.
38. Nakata M., Nagasaka S., Kusaka I., et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycemic control. Diabetologia 2006, 49:1881-1892.
39. Chamberlain L.H. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett 2001, 507:357-361.
40. Kanda M., Satoh K., Ichihara K. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull 2003, 26:1681-1684.
41. Koh K., Sakuma I., Quon M. Differential metabolic effects of distinct statins. Atherosclerosis 2011, 215:1-8.
42. Takagi T., Matsuda M., Abe M., et al. Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis 2008, 196:114-121.
43. Baker W.L., Talati R., White C.M., Coleman C.I. Differing effects of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010, 87:98-107.
44. Wannamethee S.G., Shaper A.G., Lennon L., Morris R.W. Metabolic syndrome vs Framingham risk score for prediction of coronary heat disease, stroke and type 2 diabetes mellitus. Arch Intern Med 2005, 165:2644-2650.
45. Hanley A.J.G., Karter A.J., Williams K., et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome. The insulin resistance atherosclerosis study. Circulation 2005, 112:3713-3721.
46. Wilson P.F., D'Agostino R.B., Parise H., Sullivan L., Meigs J.B. Metabolic syndrome as a predictor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112:3066-3072.
47. Lorenzo C., Okoloise M., Williams K., et al. The metabolic syndrome as a predictor of type 2 diabetes. The San Antonio heart study. Diabetes Care 2003, 26:3153-3159.
48. the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease.
49. Hill A.B. The environment and disease: association or causation?. Proc R Soc Med 1965, 58:295-300.
50. Glasziou P., Chalmers I., Rawlins M., McCulloch P. When are randomized trials necessary?. Picking signal from noise. BMJ 2007, 334:349-351.
51. Genest J., McPherson R., Frohlich J., et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol 2009, 25:567-579.
52. Mancini G.B.J., Baker S., Bergeron J., et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol 2011, 27:635-662.